XTX Topco Ltd Lowers Stock Holdings in ADMA Biologics Inc (NASDAQ:ADMA)

XTX Topco Ltd cut its holdings in shares of ADMA Biologics Inc (NASDAQ:ADMA) by 47.8% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 12,073 shares of the biotechnology company’s stock after selling 11,034 shares during the quarter. XTX Topco Ltd’s holdings in ADMA Biologics were worth $240,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in the business. Skandinaviska Enskilda Banken AB publ acquired a new stake in shares of ADMA Biologics during the 1st quarter worth $35,000. Tsfg LLC acquired a new stake in ADMA Biologics in the 1st quarter valued at $51,000. Harvest Fund Management Co. Ltd acquired a new stake in ADMA Biologics in the 1st quarter valued at $52,000. Farther Finance Advisors LLC increased its holdings in ADMA Biologics by 1,149.1% in the 1st quarter. Farther Finance Advisors LLC now owns 2,723 shares of the biotechnology company’s stock valued at $53,000 after purchasing an additional 2,505 shares in the last quarter. Finally, GF Fund Management CO. LTD. acquired a new stake in ADMA Biologics in the 4th quarter valued at $85,000. 75.68% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, Director Lawrence P. Guiheen sold 20,000 shares of the company’s stock in a transaction on Monday, June 9th. The shares were sold at an average price of $20.96, for a total value of $419,200.00. Following the completion of the sale, the director directly owned 94,830 shares in the company, valued at approximately $1,987,636.80. This represents a 17.42% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Steve Elms sold 194,749 shares of the company’s stock in a transaction on Monday, June 16th. The stock was sold at an average price of $20.24, for a total transaction of $3,941,719.76. Following the completion of the sale, the director owned 87,330 shares of the company’s stock, valued at $1,767,559.20. This represents a 69.04% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 464,621 shares of company stock worth $9,644,269. Corporate insiders own 3.70% of the company’s stock.

Wall Street Analysts Forecast Growth

ADMA has been the subject of several recent research reports. Raymond James Financial increased their price target on ADMA Biologics from $25.00 to $32.00 and gave the company a “strong-buy” rating in a report on Thursday, May 8th. Wall Street Zen downgraded ADMA Biologics from a “hold” rating to a “sell” rating in a report on Friday, May 9th.

ADMA Biologics Price Performance

Shares of NASDAQ:ADMA opened at $16.76 on Wednesday. The firm’s 50 day moving average is $18.48 and its two-hundred day moving average is $18.84. ADMA Biologics Inc has a 52 week low of $13.50 and a 52 week high of $25.67. The firm has a market capitalization of $4.00 billion, a P/E ratio of 19.49 and a beta of 0.38. The company has a current ratio of 5.33, a quick ratio of 2.78 and a debt-to-equity ratio of 0.21.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings data on Wednesday, August 6th. The biotechnology company reported $0.15 EPS for the quarter, beating analysts’ consensus estimates of $0.14 by $0.01. The business had revenue of $121.98 million for the quarter, compared to analyst estimates of $121.77 million. ADMA Biologics had a net margin of 44.06% and a return on equity of 41.01%. The business’s revenue for the quarter was up 13.8% on a year-over-year basis. During the same quarter last year, the business earned $0.13 earnings per share. Analysts anticipate that ADMA Biologics Inc will post 0.51 earnings per share for the current year.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.